{
  "id": "5ac0f7b919833b0d7b000006",
  "type": "list",
  "question": "What are the 3 antidotes for anticoagulant (anti-blood clotting) drugs, including factor Xa inhibitors, as of November 2017.",
  "ideal_answer": " two potential reversal agents for oral direct factor Xa inhibitors (andexanet alfa and ciraparantag) are at various stages of clinical development. Idarucizumab, a reversal agent for the oral direct thrombin inhibitor dabigatran, was approved by FDA in October 2015.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27895055",
    "http://www.ncbi.nlm.nih.gov/pubmed/27789605",
    "http://www.ncbi.nlm.nih.gov/pubmed/27626268"
  ],
  "snippets": [
    {
      "text": " two potential reversal agents for oral direct factor Xa inhibitors (andexanet alfa and ciraparantag) are at various stages of clinical development. Idarucizumab, a reversal agent for the oral direct thrombin inhibitor dabigatran, was approved by FDA in October 2015.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27895055",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab and andexanet alfa have been reported to produce anticoagulation reversal effects within minutes of administration. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27895055",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab has recently been approved in United States for dabigatran reversal, whereas andexanet alfa is expected to get approved in the near future for reversal of oral factor Xa inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789605",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ". Aripazine has shown promising results to reverse the effects of LMWH, fondaparinux, and direct oral anticoagulants but is still in the developmental phase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789605",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Protamine sulfate reverses the effect of unfractionated heparin completely and of low-molecular-weight heparin (LMWH) partially.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789605",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " working out pharmaceutical agents (andexanet alpha, idarucizumab, aripazine) being antidotes to direct thrombin inhibitor and the factor Xa inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27626268",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Idarucizumab, andexanet alfa, ciraparantag, Protamine sulfate, Aripazine"
}